Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.66 |
| ▸ | HSD11B1 | P28845 | 15/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | RBP4 | P02753 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22668886 | 0.83 | EPHX2 (0.73) | EPHX2HSD11B1GAARBP4MAPT | |
| SCHEMBL22669112 | 0.82 | EPHX2 (0.71) | EPHX2HSD11B1GAARBP4MAPT | |
| SCHEMBL1366662 | 0.81 | EPHX2 (0.69) | EPHX2HSD11B1GAARBP4MAPT | |
| SCHEMBL30582915 | 0.79 | EPHX2 (0.68) | EPHX2HSD11B1GAARBP4MAPT | |
| SCHEMBL1375423 | 0.79 | EPHX2 (0.68) | EPHX2HSD11B1GAARBP4MAPT | |
| SCHEMBL1375425 | 0.79 | EPHX2 (0.68) | EPHX2HSD11B1GAARBP4MAPT | |
| SCHEMBL233710 | 0.79 | EPHX2 (1.00) | EPHX2HSD11B1GAAMAPTTSHR | |
| SCHEMBL1367550 | 0.79 | EPHX2 (0.52) | EPHX2HSD11B1GAA | |
| SCHEMBL2844754 | 0.79 | LMNA (0.59) | EPHX2HSD11B1LMNAMAPT | |
| SCHEMBL27761289 | 0.78 | HSD11B1 (0.55) | EPHX2HSD11B1GAARBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9738649-B2 | Tetrahydro-pyrimidoazepines as modulators of TRPV1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2017-08-22 | — | — | US | disclosed |
| US-20160318942-A1 | TETRAHYDRO-PYRIMIDOAZEPINES AS MODULATORS OF TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-03 | — | — | US | disclosed |
| US-9422293-B2 | Tetrahydro-pyrimidoazepines as modulators of TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2016-08-23 | — | — | US | disclosed |
| US-20140135311-A1 | TETRAHYDRO-PYRIMIDOAZEPINES AS MODULATORS OF TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-15 | — | — | US | disclosed |
| EP-2024368-B1 | 6,7,8,9-TETRAHYDRO-5H-PYRIMIDO[4,5-D]AZEPIN-4-YL]-AMINE DERIVATIVES AS MODULATORS OF TRPV1 FOR THE TREATMENT OF PAIN | JANSSEN PHARMACEUTICA NV (BE) | 2014-04-30 | — | — | EP | disclosed |
| US-8673895-B2 | Tetrahydro-pyrimidoazepines as modulators of TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2014-03-18 | — | — | US | disclosed |
| US-20110288129-A1 | AMIDE DERIVATIVES AS TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2011-11-24 | — | — | US | disclosed |
| US-7998982-B2 | Amide derivatives as TRPV1 antagonists | ABBOTT LABORATORIES (US) | 2011-08-16 | — | — | US | disclosed |
| CN-101801953-A | Tetrahydropyridyl carboxamide derivatives as TRPV1 antagonists | ABBOTT LAB | 2010-08-11 | — | — | CN | disclosed |
| EP-2185538-A2 | TETRAHYDROPYRIDINE CARBOXAMIDE DERIVATIVES AS TRPVL ANTAGONISTS | Abbott Laboratories (US) | 2010-05-19 | — | — | EP | disclosed |
| US-7348343-B2 | Amides useful for treating pain | ABBOTT LABORATORIES INC. (US) | 2008-03-25 | — | — | US | disclosed |
| US-20070225275-A1 | Tetrahydro-pyrimidoazepines as modulators of TRPV1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-27 | — | — | US | disclosed |
| WO-2007109355-A2 | 6,7,8, 9 -TETRAHYDRO- 5H- PYRIMIDO [4, 5-D] AZEPIN-4-YL] -AMINE DERIVATIVES AS MODULATORS OF TRPVL FOR THE TREATMENT OF PAIN | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-27 | — | — | WO | disclosed |
| US-20070010557-A1 | Novel amides useful for treating pain | ABBVIE INC. | 2007-01-11 | — | — | US | disclosed |
| US-7129235-B2 | Amides useful for treating pain | ABBOTT LABORATORIES (US) | 2006-10-31 | — | — | US | disclosed |
| CN-1849315-A | Novel nitrogen-containing heterocyclic amides for the treatment of pain | ABBOTT LAB (US) | 2006-10-18 | — | — | CN | disclosed |
| EP-1646621-A2 | NOVEL AZAHETEROCYCLIC AMIDES USEFUL FOR TREATING PAIN | Abbott Laboratories (US) | 2006-04-19 | — | — | EP | disclosed |
| US-20050080095-A1 | administering a therapeuitcally effective amount of 3'-(trifluoromethyl)-N-{4-[(trifluoromethyl)sulfonyl]phenyl}-3,6-dihydro-2H-1,2'-bipyridine-4-carboxamide; antagonists of vanilloid receptor subtype I | ABBVIE INC. | 2005-04-14 | — | — | US | disclosed |
| WO-2005007642-A2 | NOVEL AZAHETEROCYCLIC AMIDES USEFUL FOR TREATING PAIN | ABBOTT LABORATORIES (US) | 2005-01-27 | — | — | WO | disclosed |
| US-20050009841-A1 | Novel amides useful for treating pain | ABBOTT LABORATORIES | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318942-A1 | TETRAHYDRO-PYRIMIDOAZEPINES AS MODULATORS OF TRPV1 | TRPV1, TRPA1, TRPV2 | EPHX2 1579/4885HSD11B1 2987/4885GAA 3383/4885 |
| US-20050009841-A1 | Novel amides useful for treating pain | OPRL1, OPRK1, FAAH2 | EPHX2 948/4885HSD11B1 2183/4885GAA 2322/4885 |
| US-20140135311-A1 | TETRAHYDRO-PYRIMIDOAZEPINES AS MODULATORS OF TRPV1 | TRPV1, TRPA1, TRPV2 | EPHX2 1579/4885HSD11B1 2987/4885GAA 3383/4885 |
| US-20050080095-A1 | administering a therapeuitcally effective amount of 3'-(trifluoromethyl)-N-{4-[(trifluoromethyl)sulfonyl]phenyl}-3,6-dihydro-2H-1,2'-bipyridine-4-carboxamide; antagonists of vanilloid receptor subtype I | TRPV1, OPRL1, TRPV6 | EPHX2 2882/4885HSD11B1 4395/4885GAA 2594/4885 |
| US-20070225275-A1 | Tetrahydro-pyrimidoazepines as modulators of TRPV1 | TRPV1, TRPA1, TRPV2 | EPHX2 1697/4885HSD11B1 3033/4885GAA 3378/4885 |
| US-20110288129-A1 | AMIDE DERIVATIVES AS TRPV1 ANTAGONISTS | TRPV1, TRPV3, TRPA1 | EPHX2 912/4885HSD11B1 3218/4885GAA 3258/4885 |
| US-20070010557-A1 | Novel amides useful for treating pain | OPRL1, PDE6B, PDE6G | EPHX2 823/4885HSD11B1 3143/4885GAA 1355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.